Dr. Perez-Soler on the Utility of Liquid Biopsy in Lung Cancer

Video

In Partnership With:

Roman Perez-Soler, MD, discusses the utility of liquid biopsy in lung cancer.

Roman Perez-Soler, MD, chairman, Department of Oncology, chief, Division of Medical Oncology, Montefiore Medical Center, and professor of medicine and molecular pharmacology, Albert Einstein College of Medicine, discusses the utility of liquid biopsy in lung cancer.

Liquid biopsy allows for detection of molecular abnormalities by sequencing circulating tumor DNA (ctDNA) without an invasive procedure, explains Perez-Soler. Despite some controversy surrounding liquid biopsy, 70% to 80% of tests provide viable results, says Perez-Soler.

Tumor biopsy may be recommended for the 20% to 30% of cases where not enough ctDNA was present in the peripheral blood. However, because tumor biopsy is testing the DNA in a single lesion, the results may differ from peripheral blood testing, which encompasses DNA from all metastatic sites, explains Perez-Soler.

As such, Perez-Soler advises both liquid biopsy and tumor biopsy be performed when possible to provide complementary results.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,